# Cursed 'Blood Mew' Misprinted Pokémon Cards Have Collectors and Resellers Locked in Battle
The Pokémon Company has accidentally manufactured one of the trading card game's most sought-after recent rarities, and the secondary market is in chaos.
A printing error in the 30th anniversary set has produced misprinted Mew cards with a distinctly reddish hue rather than the standard pink coloration. Collectors have dubbed these cards "Blood Mew" variants, and they've become instant targets for resellers capitalizing on scarcity and collector obsession.
The irony cuts deep. The 30th anniversary set existed specifically to address The Pokémon Company's chronic inventory shortages that have plagued the TCG market for years. Cards flew off shelves throughout 2021 and 2022, creating a secondary market frenzy that saw booster boxes sell for multiples of retail price. Stock normalcy was the goal. Instead, this printing mistake has created exactly the kind of artificial scarcity that drives collector mania and reseller profits.
The error appears isolated to specific production batches. Not every pack contains a Blood Mew, making the variant unpredictable and harder to track. This randomness intensifies demand. Collectors hunting for the variant are buying multiple boxes and packs at retail, hoping to pull one. That activity artificially inflates demand for the entire 30th anniversary set, contradicting the original purpose of wider availability.
Early resale prices already reflect the chaos. Ungraded Blood Mew cards are fetching $100 to $300 on secondary markets, with some sellers pricing them higher based on condition. Graded specimens submitted to PSA and Beckett are commanding premiums that dwarf their intended retail value. A single card from a $4 pack is now a speculative asset.
The Pokémon Company faces a familiar problem. Acknowledge the misprints as official variants and they legitimize premium pricing and rewarding resellers. Treat them as manufacturing defects warranting replacement programs and collectors grow hostile toward any company action that devalues their pulls. Either path creates backlash from different segments of the player base.
This also highlights ongoing tensions within the Pokémon TCG community between players who open cards to use them and collectors who view cards primarily as investment vehicles. The Blood Mew situation caters entirely to speculators. Competitive players benefit zero from a card variant they can't distinguish from standard versions in tournament play. But resellers now have fresh urgency to acquire remaining stock.
The 30th anniversary set was meant to celebrate the franchise and address supply complaints that had dominated headlines for eighteen months. Instead it's delivered a reminder that even well-intentioned reprints and new releases cannot escape the secondary market mechanics that now define the modern Pokémon TCG landscape. Manufacturing errors have become features, not bugs, for a community that profits from scarcity.
The Pokémon Company has not issued an official statement acknowledging the Blood Mew variants or clarifying whether they intend action. That silence allows speculation to build. The secondary market thrives on uncertainty, and The Pokémon Company's lack of transparency appears to be extending the frenzy indefinitely.